Menopause is often reduced to hot flushes. That misses the bigger clinical picture.

For many women, menopause is a major biological transition affecting sleep, mood, body composition, bone density, cardiovascular risk, sexual health and urinary function. The symptoms are real. But the physiology behind them deserves just as much attention.

Menopause is not just a symptom checklist

The fall in oestrogen through perimenopause and menopause can affect multiple systems. Some women mainly notice vasomotor symptoms: hot flushes, night sweats and disrupted sleep. Others present with mood changes, joint aches, brain fog, reduced libido, weight gain around the abdomen, recurrent urinary symptoms, vaginal dryness or pain with sex.

Some women have very few obvious symptoms but still have clinically relevant changes in bone density, cardiometabolic risk or body composition. This is why good menopause care should not stop at asking, "Are you having hot flushes?"

Bone health needs to be part of the conversation

Accelerated bone loss around menopause is clinically important. For some women, menopause hormone therapy may form part of a bone-protective strategy, particularly when symptoms are present and there are no contraindications. For others, the priority may be calcium adequacy, vitamin D, resistance training, impact loading, falls risk reduction, DEXA monitoring or osteoporosis-specific medication.

The key is not guessing. It is assessing risk and monitoring properly.

Sleep, mood and body composition are connected

Poor sleep during menopause is not trivial. When sleep becomes fragmented, it can worsen pain sensitivity, appetite regulation, insulin resistance, mood, training recovery and daytime function.

At the same time, many women notice changes in body composition: less lean mass, more central adiposity and greater difficulty maintaining previous exercise or nutrition patterns. This is not a failure of discipline. It is a change in physiology interacting with stress, sleep, training load, protein intake, alcohol, medications, injury history and life demands. A useful plan should consider all of those factors.

Genitourinary symptoms are commonly missed

Genitourinary syndrome of menopause can include vaginal dryness, irritation, painful sex, urinary urgency and recurrent urinary tract infections. These symptoms often persist or worsen without treatment.

Local vaginal oestrogen is an important option for many women. It can be used with very low systemic absorption and may be appropriate even when systemic menopause hormone therapy is not being used. As always, individual history matters, especially in women with hormone-sensitive cancer histories. This is an area where silence causes unnecessary morbidity.

MHT needs governance, not guesswork

Menopause hormone therapy can be very effective for vasomotor symptoms and can support bone health in appropriately selected women. But it should be prescribed with structure:

  • A proper history
  • Contraindication screening
  • Breast and cervical screening review
  • Bleeding assessment where relevant
  • Discussion of route, dose and formulation
  • Clear follow-up and monitoring of response and adverse effects
  • Attention to progesterone if the uterus is present
  • Consideration of vaginal oestrogen for GSM

The decision is not simply "hormones or no hormones". The better question is: what is this woman's symptom burden, risk profile, health goals and safest evidence-informed treatment pathway?

Menopause care should be structured, monitored and individualised. Done well, it is not just about symptom relief. It is about helping women maintain sleep, strength, bone health, metabolic health, sexual health and quality of life through midlife and beyond.

This is not personalised medical advice. Please consult your own doctor for advice specific to your health.